Tenderwize
Back to tender search

Non-exclusive Ibuprofen Discount Agreement

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Feb 28, 2027 · 190 days left·Open·Supplies·Framework
Sign up to saveOpen documents
Original notice title

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ibuprofen (ATC-Code nach WHO: M01AE01)

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

40 / 100

Complexity

30 / 100

Risk factors

Unknown demand and no guaranteed minimum volumes; actual revenue is highly uncertain.

Agreement may be terminated early if exclusive discount agreements are signed by AOK PLUS.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Feb 2027
  • Supply of Ibuprofen film tablets (ATC M01AE01) under a non-exclusive discount agreement
  • Pharmaceutical companies must be eligible under § 130a Abs. 8 SGB V and § 4 Abs. 18 AMG
Show full summary

Non-exclusive drug discount agreement (Rabattvereinbarung) for Ibuprofen (ATC M01AE01) film tablets under an Open House model with AOK PLUS. The agreement is open to all qualified pharmaceutical companies during the participation period. No guaranteed minimum quantities, no exclusive supply, and individual negotiations are not conducted. The agreement ends 28 February 2027, with possible early termination if exclusive agreements are concluded. This publication is for transparency and not a formal public procurement under EU directives.

Risks

Unknown demand and no guaranteed minimum volumes; actual revenue is highly uncertain.

Agreement may be terminated early if exclusive discount agreements are signed by AOK PLUS.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical company as defined in § 4 Abs. 18 AMG with respect to the offered drugs

Eligibility

  • Submit declaration of no exclusion grounds (§§ 123, 124 GWB)

Administrative

  • Submit declaration regarding EU Russia sanctions (Art. 5k of Regulation (EU) 2022/576)

Award Criteria

Lot 1

No award criteria specified; this is a non-competitive Open House model, not a traditional tender.

Buyer

Location

Erfurt, DEU

Buyer profile

Open profile

Identifier

DE256878834

Activity

Health

Lots (1)

LOT-0001

Non-exclusive Ibuprofen Discount Agreement

Conclusion of non-exclusive discount agreements for prescription drugs with active ingredient Ibuprofen (ATC M01AE01) in film tablet form. Open House model: any interested pharmaceutical company can join if they meet the conditions. No minimum purchase quantities, unknown demand dependent on prescription behavior.

SuppliesFrameworkEU fundedElectronic submission

Location

Dresden, Germany

Duration

May 2025 - Feb 2027

Category

Pharmaceutical products

Award Criteria

No award criteria specified; this is a non-competitive Open House model, not a traditional tender.

Deadline

Expired May 05, 2025

Procurement Details

Publication date
13 Feb 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
102408-2025

Documents (1)

Procurement document 1

Similar tenders

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3